<DOC>
	<DOC>NCT00828022</DOC>
	<brief_summary>The objectives of the study are to assess the efficacy and safety of live, attenuated measles vaccine as consolidation therapy in patients with measles-positive, non-small cell lung cancer with locally-advanced (stage 3B with pleural effusion) or metastatic (stage 4) tumors in remission.</brief_summary>
	<brief_title>Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>This is a single-institution, non-randomized phase 1/2 study in patients with locally-advanced or metastatic NSCLC in remission after receiving standard systemic chemotherapy of four cycles of combination chemotherapy consisting of four cycles of cisplatin combined with vinorelbine.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients in remission after firstline chemotherapy Progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>measles-positive NSCLC</keyword>
	<keyword>measles vaccine</keyword>
	<keyword>consolidation</keyword>
	<keyword>Stage 3B with pleural effusion or stage 4 non-small cell lung cancer in remission</keyword>
</DOC>